What is the dosage of venetoclax? How much should you take daily?

Venetoclax is a targeted therapy drug mainly used for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). When using venetoclax, the patient's specific condition will affect the dosage of the drug, so it needs to be adjusted according to the individualized treatment plan. This article will detail the dosage of venetoclax and its administration regimen to help patients understand and use the drug correctly.

For patients with chronic lymphocytic leukemia and small lymphocytic lymphoma, dosing of venetoclax begins with a 5-week ramp-up phase. The purpose of this phase is to gradually reduce tumor burden and reduce the risk of tumor lysis syndrome (TLS). The specific dosage schedule is as follows: in the first week, patients take 20 mg orally daily; increase to 50 mg in the second week; 100 mg in the third week; 200 mg in the fourth week; and maintain the dose of 400 mg once a day in the fifth week and beyond.

If used in combination with otuzumab, dosing of venetoclax begins on day 22 of cycle 1 according to the 5-week accelerated dosing schedule described above. After completing the ramp-up period, continue taking 400 mg orally daily starting on the first day of cycle three until the last day of cycle 12. When used in combination with rituximab, rituximab was initiated after the patient completed a 5-week escalating dose regimen of venetoclax and received the recommended dose of 400 mg of venetoclax orally once daily for 7 days. Beginning on day 1 of rituximab cycle 1, continue venetoclax 400 mg orally once daily for 24 months.

In acute myeloid leukemia (AML), the dosing schedule for venetoclax is slightly different, depending on the other drugs it is combined with. For patients with AML, a 3- or 4-day dose escalation schedule is typically used. The details are as follows: take 100 mg orally on the first day, 200 mg orally on the second day, and 400 mg orally on the third day. Starting from the fourth day, if combined with azacitidine or decitabine, patients can take 400 mg orally once a day, every 28 days; if combined with low-dose cytarabine, take 600 mg orally once a day, every 28 days.

In order to ensure the effectiveness and safety of venetoclax, patients should be reviewed regularly during medication to monitor hematological indicators and possible side effects. At the same time, patients should follow medical advice and not adjust the dosage without authorization. In addition, understanding possible drug interactions and how to deal with adverse reactions are also critical to the effectiveness of treatment.

In short, the dosage of venetoclax should be individually adjusted according to the patient's specific situation and follow the guidance of professional physicians to ensure safe and effective treatment.

References:

https://www.drugs.com/pro/venclexta.html#_2_6_Dosage_Modifications